Bayer HealthCare / Press

Stivarga® (regorafenib) from Bayer Approved in the European Union for the Treatment of Gastrointestinal Stromal Tumors

The oncology compound Stivarga® (regorafenib) from Bayer has been approved by the European Commission (EC) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib. more      

In Focus

Healthcare News

Photos & Videos

  • Photos

    Photo galleries with topic-related images.

  • TV Footage

    In this section you can find videos for editorial coverage.

Bayer HealthCare Links

Annual report Integrated Annual Report of Bayer AG 2013
RSS Feed
RSS Feed

Copyright © Bayer HealthCare AG